Literature DB >> 18768874

A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.

Damian M Carragher1, Denise A Kaminski, Amy Moquin, Louise Hartson, Troy D Randall.   

Abstract

Current influenza vaccines elicit Abs to the hemagglutinin and neuraminidase envelope proteins. Due to antigenic drift, these vaccines must be reformulated annually to include the envelope proteins predicted to dominate in the following season. By contrast, vaccination with the conserved nucleoprotein (NP) elicits immunity against multiple serotypes (heterosubtypic immunity). NP vaccination is generally thought to convey protection primarily via CD8 effector mechanisms. However, significant titers of anti-NP Abs are also induced, yet the involvement of Abs in protection has largely been disregarded. To investigate how Ab responses might contribute to heterosubtypic immunity, we vaccinated C57BL/6 mice with soluble rNP. This approach induced high titers of NP-specific serum Ab, but only poorly detectable NP-specific T cell responses. Nevertheless, rNP immunization significantly reduced morbidity and viral titers after influenza challenge. Importantly, Ab-deficient mice were not protected by this vaccination strategy. Furthermore, rNP-immune serum could transfer protection to naive hosts in an Ab-dependent manner. Therefore, Ab to conserved, internal viral proteins, such as NP, provides an unexpected, yet important mechanism of protection against influenza. These results suggest that vaccines designed to elicit optimal heterosubtypic immunity to influenza should promote both Ab and T cell responses to conserved internal proteins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18768874      PMCID: PMC2590646          DOI: 10.4049/jimmunol.181.6.4168

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Development of effective vaccines against pandemic influenza.

Authors:  Kanta Subbarao; Brian R Murphy; Anthony S Fauci
Journal:  Immunity       Date:  2006-01       Impact factor: 31.745

2.  Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA.

Authors:  J B Ulmer; T M Fu; R R Deck; A Friedman; L Guan; C DeWitt; X Liu; S Wang; M A Liu; J J Donnelly; M J Caulfield
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

3.  Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.

Authors:  A D Altstein; A K Gitelman; Y A Smirnov; L M Piskareva; L G Zakharova; G V Pashvykina; M M Shmarov; O P Zhirnov; N P Varich; P O Ilyinskii; A M Shneider
Journal:  Arch Virol       Date:  2005-11-15       Impact factor: 2.574

4.  Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon.

Authors:  Wassim Chehadeh; Pierre-Emmanuel Lobert; Pierre Sauter; Anne Goffard; Bernadette Lucas; Jacques Weill; Marie-Christine Vantyghem; Gunnar Alm; Pascal Pigny; Didier Hober
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein.

Authors:  S Tamura; K Miyata; K Matsuo; H Asanuma; H Takahashi; K Nakajima; Y Suzuki; C Aizawa; T Kurata
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

6.  Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.

Authors:  S Sambhara; A Kurichh; R Miranda; T Tumpey; T Rowe; M Renshaw; R Arpino; A Tamane; A Kandil; O James; B Underdown; M Klein; J Katz; D Burt
Journal:  Cell Immunol       Date:  2001-08-01       Impact factor: 4.868

7.  Early presence of ribonucleoprotein antigen on surface of influenza virus-infected cells.

Authors:  J L Virelizier; A C Allison; J S Oxford; G C Schild
Journal:  Nature       Date:  1977-03-03       Impact factor: 49.962

8.  Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes.

Authors:  H H Nguyen; H L Vu; J R McGhee; J Mestecky
Journal:  J Infect Dis       Date:  2000-12-20       Impact factor: 5.226

9.  CD4 T cell-independent antibody response promotes resolution of primary influenza infection and helps to prevent reinfection.

Authors:  Byung O Lee; Javier Rangel-Moreno; Juan E Moyron-Quiroz; Louise Hartson; Melissa Makris; Frank Sprague; Frances E Lund; Troy D Randall
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

10.  Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin.

Authors:  P A Scherle; W Gerhard
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

View more
  130 in total

1.  Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism.

Authors:  Yuan Fang; David Banner; Alyson A Kelvin; Stephen S H Huang; Christopher J Paige; Steven A Corfe; Kevin P Kane; R Chris Bleackley; Thomas Rowe; Alberto J Leon; David J Kelvin
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

Review 2.  Protective B cell responses to flu--no fluke!

Authors:  Elizabeth E Waffarn; Nicole Baumgarth
Journal:  J Immunol       Date:  2011-04-01       Impact factor: 5.422

3.  Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus.

Authors:  Jae-Min Song; Nico Van Rooijen; Jadranka Bozja; Richard W Compans; Sang-Moo Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

4.  Biopolymer encapsulated live influenza virus as a universal CD8+ T cell vaccine against influenza virus.

Authors:  Alina C Boesteanu; Nadarajan S Babu; Margaret Wheatley; Elisabeth S Papazoglou; Peter D Katsikis
Journal:  Vaccine       Date:  2010-10-27       Impact factor: 3.641

5.  A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge.

Authors:  Dongming Zhou; Te-Lang Wu; Marcio O Lasaro; Brian P Latimer; Elizabeth M Parzych; Ang Bian; Yan Li; Hua Li; Jan Erikson; Zhiquan Xiang; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

6.  Location of antigenic sites recognized by monoclonal antibodies in the influenza A virus nucleoprotein molecule.

Authors:  Natalia L Varich; Konstantin S Kochergin-Nikitsky; Evgeny V Usachev; Olga V Usacheva; Alexei G Prilipov; Robert G Webster; Nikolai V Kaverin
Journal:  J Gen Virol       Date:  2009-03-18       Impact factor: 3.891

7.  A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge.

Authors:  Timothy D Carroll; Sinthujan Jegaskanda; Shannon R Matzinger; Linda Fritts; Michael B McChesney; Stephen J Kent; Jeffery Fairman; Christopher J Miller
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226

8.  Gammaherpesvirus latency induces antibody-associated thrombocytopenia in mice.

Authors:  Michael L Freeman; Claire E Burkum; Kathleen G Lanzer; Alan D Roberts; Mykola Pinkevych; Asako Itakura; Lawrence W Kummer; Frank M Szaba; Miles P Davenport; Owen J T McCarty; David L Woodland; Stephen T Smiley; Marcia A Blackman
Journal:  J Autoimmun       Date:  2012-12-14       Impact factor: 7.094

9.  Controlling influenza by cytotoxic T-cells: calling for help from destroyers.

Authors:  Michael Schotsaert; Lorena Itatí Ibañez; Walter Fiers; Xavier Saelens
Journal:  J Biomed Biotechnol       Date:  2010-05-24

10.  Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza.

Authors:  Garry W Lynch; Paul Selleck; John S Sullivan
Journal:  J Mol Genet Med       Date:  2009-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.